HEK293 | Jotup

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Retrieved on:

Monday, April 22, 2024

TRACER, Histology, Mouse, Phenotype, Data science, Cell, AAV, CNS, Machine learning, Senior, Tauopathy, Gene, Process, Society, BBB, ALS, Central nervous system, Public, HEK293, Therapy, Centrifuge, SOD1, Vaccine

“Voyager’s novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system.

Key Points:

“Voyager’s novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system.
Three of those programs now have development candidates selected, and we see the potential for them to enter clinical trials next year,” said Todd Carter, Ph.D., Chief Scientific Officer of Voyager Therapeutics.
ET
Intravenous administration of BBB-penetrant, MAPT-Silencing, AAV gene therapy provides broad and robust CNS Tau lowering in tauopathy mouse models (#1602).
ET
Intravenous delivery of AAV gene therapy for the treatment of SOD1-ALS provides broad SOD1 lowering in NHP (#1647).

Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore

Retrieved on:

Tuesday, April 16, 2024

Rabbit, AMD, Mouse, PCV, Tropism, Cell, AAV, Sf9, Gene, Society, Sf9 (cells), Molecular Therapy, HEK293, CGMP, Vaccine

HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.

Key Points:

HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.
In addition, Avirmax will have an exhibitor booth #818 to showcase the latest progress and data package.
ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy.
Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSafTM rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations.

Avirmax Biopharma Inc. to Present at the 2024 ARVO Annual Meeting in Seattle

Retrieved on:

Monday, April 1, 2024

Research, Neuroprotection, Sf9, Glaucoma, ARVO, HEK293, HEK 293 cells

HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.

Key Points:

HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.
ARVO is the largest international society dedicated to ophthalmology and vision-related topics.
Dr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer, is invited to present "Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells", at the 2024 ARVO Symposium on "Developing gene therapy for glaucoma neuroprotection: Opportunities and challenges", May 9, 8 – 10 am.
In addition to the invited talk, there will be two more scientific presentations from Avirmax Biopharma and an exhibitor booth #1604 to showcase the latest progress and data package:

Agathos Biologics Launches Recombinant Adeno-Associated Virus Production Service Using Novel AE1-BHK Cell Line

Retrieved on:

Wednesday, March 6, 2024

Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.

Key Points:

Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.
View the full release here: https://www.businesswire.com/news/home/20240305885603/en/
The AE1-BHK cell line was developed by stable transfection of the BHK-21 (C-13) cell line (ATCC®, catalog number ATCC CCL-10™) with the adenoviral E1 gene.
“The launch of our custom rAAV service and the first sale of rAAV made using our AE1-BHK cell line is a significant milestone for the company,” said James Brown, CEO and co-founder of Agathos Biologics.
“To our knowledge, this is the first sale of rAAV produced using triple transfection in a cell line other than HEK293.

Applied Biomics Launches Anti-Host Cell Protein (HCP) Antibodies with > 95% Coverage

Retrieved on:

Thursday, February 29, 2024

Biotechnology, Science, Health, Research, HCP, LMW, HMW, WB, C6, ELISA, Proteomics, Antibody, HEK293, CHO, Map, CAP, Fine chemical

Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.

Key Points:

Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.
View the full release here: https://www.businesswire.com/news/home/20240228749573/en/
Antibody Coverage of Applied Biomics' Anti-CHO Antibody by 2D Western Blot (WB).
Following are highlights of Applied Biomics’ HCP Antibodies:
High HCP coverage: Detects well over 2500 (up to ~5000) low and high molecular weight (LMW & HMW) HCPs, with > 95% overall HCP coverage and > 90% each quadrant coverage.
With our leading HCP antibody coverage services , customers can now test Applied Biomics’ HCP antibody against their process specific HCPs, or compare with other HCP antibodies to find a better fit.

NewBiologix Licenses Florabio’s HEK293 Cell Line for the Generation of Novel and Proprietary Cell Lines for the Stable Expression of rAAVs used in Gene Therapy

Retrieved on:

Tuesday, February 27, 2024

Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, HEK, HEK293, Immortalised cell line, AAV, Research, Cell, Patient, Fine chemical

NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies.

Key Points:

NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies.
Under the terms of the agreement, NewBiologix acquired rights to use Florabio’s HEK293 suspension cell line for research and commercial applications.
Leveraging proprietary genomic data, NewBiologix plans to engineer the Florabio HEK293 cell line and select highly characterized clones with exceptional growth, expansion, and transfectability properties.
NewBiologix will achieve its goals faster and more efficiently by starting with the 'FlorabioHEK293' cell line and our chemically defined HEK293 medium.”

Matica Bio Welcomes Four Life Sciences Visionaries as Members of Advisory Board

Retrieved on:

Tuesday, October 17, 2023

Science, Stem Cells, Biotechnology, Research, Other Manufacturing, Health, Genetics, Manufacturing, HEK293, Amgen, Juno Therapeutics, CGT, Novartis, GMP, Growth, CDMO, Pharmaceutical industry

As the inaugural members of Matica Bio’s advisory board, these appointments will provide strategic oversight as the company executes the development, scale-up, and production of CGTs at its purpose-built GMP facility in Texas.

Key Points:

As the inaugural members of Matica Bio’s advisory board, these appointments will provide strategic oversight as the company executes the development, scale-up, and production of CGTs at its purpose-built GMP facility in Texas.
Combined with Matica Bio’s bespoke approach to CGT manufacturing – enabled by a fully closed, single-use platform and industry-leading analytical capabilities – the incoming leadership of this newly established advisory board will further empower the company to meet the growing demand for CGT manufacturing expertise.
“Matica Bio is thrilled to introduce the accomplished members of our newly formed board of advisors,” said Yun Jeong Song, M.D., president and chief executive officer of Matica Bio.
The formation of Matica Bio’s board of advisors comes shortly after the hiring of Laura Parks as head of commercial operations and Heather N. Sugrue as vice president of business development.

New Hope Research Foundation and Forge Biologics Announce cGMP Manufacturing Partnership to Accelerate Gene Therapy for Patients with Tay-Sachs Disease

Retrieved on:

Wednesday, June 28, 2023

View the full release here: https://www.businesswire.com/news/home/20230628556153/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20230628556153/en/
“We are proud to be the CDMO partner for New Hope Research Foundation, an organization that is significantly advancing a gene therapy approach to provide hope for patients suffering from Tay-Sachs disease,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics.
“At Forge, we are ready to partner with companies, nonprofit organizations, and gene therapy developers around the world, working towards the mission we share to bring potentially life-saving gene therapies to patients.”
Through this partnership, Forge will provide adeno-associated virus (AAV) process development, analytical services, and cGMP manufacturing to New Hope Research Foundation.
The Foundation will leverage Forge’s platform processes, including its proprietary HEK293 suspension Ignition Cells™, to accelerate the initial production.
All development and AAV manufacturing activities will occur at the Hearth, Forge’s 200,000 square foot gene therapy facility in Columbus, Ohio.

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on:

Tuesday, May 16, 2023

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 16-20, 2023 in Los Angeles, CA.

Key Points:

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 16-20, 2023 in Los Angeles, CA.
Cre-mediated recombination of ABCA4 was confirmed by mRNA sequencing of RNA from transfected HEK293 cells and AAV-dosed animals.
RS1 expression was associated with improvement in cone photoreceptor density and increased thickness of the photoreceptor outer nuclear layer.
Following intravitreal injection in wild type mice, variants 1 and 7 showed robust protein expression.

Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases

Retrieved on:

Monday, May 8, 2023

Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.

Key Points:

Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.
Through this partnership, Forge will provide adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing, and analytical services to Life Bio.
All development and AAV manufacturing activities will occur at the Hearth, Forge’s 200,000 square foot gene therapy facility in Columbus, Ohio.
“We are delighted to be working with the Forge team, whose expertise in gene therapy manufacturing is unmatched,” said Jerry McLaughlin, Chief Executive Officer of Life Biosciences.